- March 18, 2014 at 9:23 pm #117054
dvjorgeParticipantTopics: 283Replies: 1368
This is another study pointing to the use of Baker yeast to treat candidiasis.!
Protective effect of acidic mannan fraction of bakers’ yeast on experimental candidiasis in mice.
Okawa Y, Suzuki K, Kobayashi M, Asagi M, Sakai K, Suzuki S, Suzuki M.
An acidic fraction of bakers’ yeast mannan, WAM025, showed a significant protective effect against Candida albicans infection in mice, but a neutral fraction of the same bakers’ yeast mannan, WNM, did not exhibit this effect. Moreover, pretreatment with WAM025 resulted in a marked reduction of proliferation of C. albicans cells in the organs of the infected mice. We investigated the stimulative effect of these mannan fractions on the function of mouse peritoneal phagocytes, and found that mice administered WAM025 showed a greater increase in the number of peritoneal exudate cells, macrophages and polymorphonuclear leucocytes (PMN), than the mice treated with WNM, especially in the proportion of PMN. Peritoneal phagocytes, PMN and macrophages obtained from WAM025-treated mice showed marked candidacidal activity. Of the phagocytes, PMN were responsible for the larger part of the candidacidal activity. The myeloperoxidase activities of PMN and macrophages in WAM025-treated PEC were greater than in untreated macrophages. The myeloperoxidase activity of WAM025-treated PMN was significantly greater than that of WAM025-treated macrophages. This activity paralleled the active oxygen-releasing activity of the phagocytes. On the other hand, the phagocytic activity of phagocytes from mice administered WNM or WAM025 for C. albicans cells was identical to that of untreated phagocytes. WAM025 seems to cause enhance elimination of the pathogen from mice, by increasing the number and candidacidal activity of phagocytic cells.
Treatment of oral candidiasis (thrush) by
Faculty of Medical Technology, Misurata University, Misalata, Libya.
Faculty of Science, Misurata University, Misalata, Libya.
3Department of Dentistry, Al Tawfiq Polyclinic, AlKhoms, Libya.
Faculty of Science, Misurata University, AlKhoms, Libya.
5Department of Gynecology and Obstetrics, Suk Al Khamees General Hospital, Suk Al Khamees, Libya.
Almadina Medical Laboratory, AlKhoms, Libya.
Accepted 17 March, 2011
Oral candidiasis is a fungal disease caused by Candida albicans. Saccharomyces cerevisiae is a
probiotic often used as dietary supplements and in food preparation. In this study, we explored the
treatment modality of S. cerevisiae on oral candidiasis in 15 patients belonging to verum group (n = 10)
and placebo group (n = 5). All 10 patients in verum group have recovered from the oral candidiasis in 2
to 3 days whereas in the placebo group, it was a minimum of 12 days. Two patients from the verum
group did not respond to antifungal treatment with miconazole but recovered within 3 days of S.
You must be logged in to reply to this topic.